Treatment patterns and clinical outcomes in Chinese patients with NSCLC with MET alterations resistant to EGFR‑TKI therapy
Open Access
- 4 July 2025
- journal article
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 23 (3) , 1-10
Abstract
The present study evaluated therapeutic strategies and clinical outcomes in Chinese patients with mesenchymal‑epithelial transition (MET) alterations in non‑small cell lung cancer (NSCLC) who were progressing on epidermal growth factor receptor‑tyrosine kinase inhibitor (EGFR‑TKI), aiming to address the unmet need of overcoming MET‑driven resistance. A real‑world study was conducted, involving eligible patients with NSCLC treated at Jiangnan University Affiliated Hospital between February 2022 and April 2024. Based on the treatment regimen, patients were categorized into three groups: MET‑TKI combined with EGFR‑TKI, chemotherapy‑based regimen, and other regimens. The primary outcomes were the objective response rate (ORR), time to treatment failure (TTF), post‑progression survival (PPS) and adverse events (AEs). A total of 32 patients were included in the analysis. The MET‑TKI plus EGFR‑TKI group (n=10) achieved the highest ORR at 55.6%, followed by the chemotherapy‑based regimen group (n=15) at 42.9% and the other regimens group (n=7) at 14.3%. The median TTF was 9.5 months for the MET‑TKI plus EGFR‑TKI group, compared with 4.4 and 3.6 months for the chemotherapy‑based and other regimens groups, respectively (P=0.748). Similarly, the median PPS was 14.4 months in the MET‑TKI plus EGFR‑TKI group, compared with 9.4 and 7.0 months in the chemotherapy‑based and other regimens groups, respectively (P=0.733). Treatment‑related AEs varied among the groups, with nausea, peripheral edema and rash being the most common in the MET‑TKI plus EGFR‑TKI group. In conclusion, the combination of MET‑TKI and EGFR‑TKI demonstrates promising benefits in terms of TTF, PPS and ORR, underscoring its potential as a viable treatment option. The modest improvements observed, coupled with the inherent limitations of the present study, emphasize the necessity for further research to optimize treatment strategies and gain a deeper understanding of the long‑term efficacy of combination therapy in addressing MET‑driven resistance to EGFR‑TKI.Keywords
This publication has 31 references indexed in Scilit:
- Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trialThe Lancet Oncology, 2024
- Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 studyThe Lancet Respiratory Medicine, 2022
- Effects of inhalable gene transfection as a novel gene therapy for non-small cell lung cancer and malignant pleural mesotheliomaScientific Reports, 2022
- The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non‐small cell lung cancer patients with epidermal growth factor receptor mutationCancer Communications, 2021
- Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 TrialJournal of Thoracic Oncology, 2021
- Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trialThe Lancet Respiratory Medicine, 2020
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 studyLung Cancer, 2014
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFRNew England Journal of Medicine, 2010